Patents by Inventor Frank Navas

Frank Navas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzoylglycine Derivatives and Methods of Making and Using Same
    Publication number: 20210206715
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Application
    Filed: March 19, 2021
    Publication date: July 8, 2021
    Applicants: Duke University, The University of North Carolina at Chapel Hill
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
  • Benzoylglycine derivatives and methods of making and using same
    Patent number: 11034649
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: June 15, 2021
    Assignees: DUKE UNIVERSITY, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
  • Benzoylglycine derivatives and methods of making and using same
    Patent number: 10550074
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: February 4, 2020
    Assignees: DUKE UNIVERSITY, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
  • Benzoylglycine Derivatives and Methods of Making and Using Same
    Publication number: 20190367446
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Application
    Filed: April 25, 2017
    Publication date: December 5, 2019
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
  • Benzoylglycine Derivatives and Methods of Making and Using Same
    Publication number: 20190169114
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Application
    Filed: February 7, 2019
    Publication date: June 6, 2019
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
  • Farnesoid X receptor agonists
    Patent number: 8158665
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: April 17, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Richard Caldwell, David Norman Deaton, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
  • Farnesoid X receptor agonists
    Patent number: 7960552
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: June 14, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Jonathan York Bass, III, Justin Caravella, David Norman Deaton, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
  • FARNESOID X RECEPTOR AGONISTS
    Publication number: 20110034507
    Abstract: The present invention relates to farnesoid X receptors (FXR, NR1H4). FXR is a member of the nuclear receptor class of ligand-activate transcription factors. More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same. Novel isoxazole compounds are disclosed as part of pharmaceutical compositions for the treatment of a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease, liver fibrosis, and metabolic syndrome.
    Type: Application
    Filed: June 13, 2008
    Publication date: February 10, 2011
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Adwoa Akwabi-Ameyaw, David Norman Deaton, Robert Blount McFadyen, Frank Navas, III
  • Farnesoid X Receptor Agonists
    Publication number: 20100249179
    Abstract: The present invention provides novel isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Application
    Filed: June 13, 2008
    Publication date: September 30, 2010
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: David Norman Deaton, Frank Navas, III, Paul Kenneth Spearing
  • Cycloalkylidene compounds as modulators of estrogen receptor
    Patent number: 7799828
    Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: September 21, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Jing Fang, Dennis Heyer, Aaron Bayne Miller, Frank Navas, III, Terrence Lee Smalley, Jr., William J. Zuercher, Subba Reddy Katamreddy
  • Farnesoid X Receptor Agonists
    Publication number: 20100160398
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Application
    Filed: March 9, 2010
    Publication date: June 24, 2010
    Inventors: Richard Caldwell, David Norman Deaton, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
  • Farnesoid X Receptor Agonists
    Publication number: 20100120775
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Application
    Filed: October 23, 2007
    Publication date: May 13, 2010
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Jonathan York Bass, III, David Norman Deaton, Justin Caravella, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
  • Farnesoid X receptor agonists
    Patent number: 7705028
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: April 27, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Richard Caldwell, David Norman Deaton, Robert Blout McFayden, Frank Navas, III, Paul Kenneth Spearing
  • Naphthalene compounds as selective estrogen receptor modulators
    Patent number: 7649093
    Abstract: The present invention relates to cycloalkylidene compounds with a variety of therapeutic uses, more particularly novel naphthalene compounds that are particularly useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: June 21, 2005
    Date of Patent: January 19, 2010
    Assignee: Glaxo Smith Kline LLC
    Inventors: Dennis Heyer, Jing Fang, Frank Navas, III, Subba Reddy Katamreddy, Jennifer Poole Peckham, Philip Stewart Turnbull, Aaron Bayne Miller, Adwoa Akwabi-Ameyaw
  • Cycloalkylidene Compounds As Modulators of Estrogen Receptor
    Publication number: 20090253659
    Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.
    Type: Application
    Filed: June 8, 2009
    Publication date: October 8, 2009
    Inventors: Jing Fang, Dennis Heyer, Aaron Bayne Miller, Frank Navas, III, Terrence Lee Smalley, JR., William J. Zuercher, Subba Reddy Katamreddy
  • Cycloalkylidene compounds as modulators of estrogen receptor
    Patent number: 7569601
    Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: August 4, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Jing Fang, Dennis Heyer, Aaron Bayne Miller, Frank Navas, III, Terrence Lee Smalley, Jr., William J. Zuercher, Subba Reddy Katamreddy
  • Cycloalkylidene compounds as modulators of estrogen receptor
    Patent number: 7560589
    Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: July 27, 2004
    Date of Patent: July 14, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Jonathan E. Britton, Jing Fang, Dennis Heyer, Aaron Bayne Miller, Frank Navas, III, Terrence Lee Smalley, Jr., William J. Zuercher, Subba Reddy Katamreddy
  • FARNESOID X RECEPTOR AGONISTS
    Publication number: 20080167356
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Application
    Filed: December 13, 2006
    Publication date: July 10, 2008
    Applicant: SmithKline Beecham Corporation
    Inventors: Richard CALDWELL, David Norman Deaton, Robert Blount McFayden, Frank Navas, Paul Kenneth Spearing
  • FARNESOID X RECEPTOR AGONISTS
    Publication number: 20080096921
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Application
    Filed: October 23, 2007
    Publication date: April 24, 2008
    Applicant: SmithKline Beecham Corporation
    Inventors: Frank NAVAS, Paul Spearing
  • CHEMICAL COMPOUNDS
    Publication number: 20070276000
    Abstract: The present invention relates to cycloalkylidene compounds with a variety of therapeutic uses, more particularly novel naphthalene compounds that are particularly useful for selective estrogen modulation.
    Type: Application
    Filed: June 21, 2005
    Publication date: November 29, 2007
    Inventors: Dennis Heyer, Jing Fang, Frank Navas III, Subba Katamreddy, Jennifer Peckham, Philip Turnbull, Aaron Miller, Adwoa Akwabi-Ameyan, Charles Dadswell